Oculis Holding AG

OCS · Nasdaq · Healthcare · Biotechnology

Next earnings: November 9, 2026

$9.04-2.5%Sep 28 close

1M: -26.0%
6M: -63.4%
1Y: -48.5%
5Y: -7.2%

Built from Oculis Holding AG’s own filings with the SEC. Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Full financial statements →

How it compares with its industry

Three ratings, each a percentile against the 585 companies we cover in Biotechnology. Deliberately kept apart rather than blended into one score — cheap, rising and well-run are three different facts, and a single number would hide which one is which.

Momentum

39of 100 in its industry

Below most of its industry

12 months to a month ago-25.3%

6 months to a month ago-58.5%

The most recent month is left out on purpose: returns tend to persist over 7–12 months and the newest one tends to reverse. This describes what the price has done, and says nothing about what it will do.

Value

44of 100 in its industry

Middle of its industry

Profit for the price-20.16%

Cash for the price-16.96%

Sales for the price—

Assets for the price49.91%

Operating profit for the whole business0.56%

Yields, so higher means cheaper — a loss-making company ranks last instead of dropping out. Cheap is not the same as good: a high yield is often a price that fell for a reason. Blended from 4 of 5 measures.

Capital allocation

1/3Mixed

3 checks not reported

Return on capital0.5%

Shareholder yield—

Share count, 3 years1,647.6%

Net debt / EBITDA-45.74x

Insiders, 12 months—

What management does with the money — scored on whatever the filings answer, never as a share of the total.

The six capital-allocation checks

Return on the money invested0.5% on invested capital
Debt against earningsMore cash than debt
Cash returned to shareholdersNeither buybacks nor dividends reported
Share count over three yearsShare count 1,647.6% higher over three years
Payouts covered by cash flowNot enough reported to compare
Open-market insider buyingNo open-market insider dealing on file

A description of where this company sits among its competitors, not a recommendation. Ratings updated Sep 29, 2026.

This company files in CHF. Figures are converted to US dollars at $1.00 = 0.831780 CHF, the current rate, applied to every period alike — so growth and margins are the company’s own and not the exchange rate’s.

Not rated

Is the business getting bigger, and does it generate real cash?

Only 3 of the 5 checks below could be answered from this company’s filings, which is too few to put it on the scale. The filings do not go back far enough for the year-on-year comparisons these checks need. Whatever did resolve is still shown — it is just not enough for a letter.

There is no grade history to chart for Oculis Holding AG yet. The quarterly grade is rebuilt from only the filings that were public at the time, and this company has not yet reported enough of them to score a single quarter.

Oculis Holding AG

How it compares with its industry

Growth & cash — 0 of 3